表紙
市場調査レポート

Azilect(パーキンソン病治療薬):市場の予測と分析

Azilect (Parkinson's Disease) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 217326
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Azilect(パーキンソン病治療薬):市場の予測と分析 Azilect (Parkinson's Disease) - Forecast and Market Analysis to 2022
出版日: 2014年03月31日 ページ情報: 英文 61 Pages
概要

Azilect(ラサギリン)は第二世代のMAO-B阻害薬で、Teva Pharmaceuticalsによりパーキンソン病の治療薬として開発されました。Azilectは早期段階にあるパーキンソン病の単剤治療薬(1日1回、1mg)として、またレボドパに対する補助療法(1日1回、必要に応じて0.5〜1mg)(Azilect package insert, 2012)として認可されています。

当レポートでは、パーキンソン病の治療薬の一つ、Azilectの世界市場について分析し、疾患の概要や治療法、競合する企業・薬品の概要、市場競争の概況、Azilectの商品情報(特色・効能・安全性など)、世界の主要国における市場販売額の見通し(今後10年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 当レポートの概要
  • 関連調査

第3章 疾患の概要

  • 病因と病態
    • 病因
    • 病態生理
    • 予後
    • QoL(生活の質)
  • 症状

第4章 疾患管理

  • 概要
    • 診断:The UK Brain Bankの評価基準
    • 治療ガイドラインと主な処方薬
  • 治療法の概要
    • ドーパミン作動系療法のクラス
    • パーキンソン病の段階別の治療法
    • その他の治療オプション
  • パーキンソン病の評価スケール
    • パーキンソン病統一スケール(UPDRS)
    • Hoehn and Yahrの病期分類
    • その他の臨床評価方法

第5章 競合企業の評価

  • 概要
  • 競合企業の戦略的評価
  • 製品プロファイル:MAO-B阻害薬

第6章 Azilect(ラサギリン)について

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 将来予測

第7章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC396DFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Azilect (rasagiline) is a second-generation MAO-B inhibitor, developed by Teva Pharmaceuticals for the treatment of the signs and symptoms of Parkinson's disease. Azilect is approved for use as a monotherapy in early Parkinson's disease at a once-daily dosage of 1mg, or as an adjunctive therapy to levodopa at 0.5mg or 1mg, as needed, once daily (Azilect package insert, 2012).

Scope

  • Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Azilect including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Azilect for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Brazil.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Azilect performance
  • Obtain sales forecast for Azilect from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Brazil).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's Disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - MAO-B Inhibitors

6. Azilect (rasagiline)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Parkinson's Disease Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Compliance Assumptions
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 9: Leading Treatments for Parkinson's Disease, 2014
  • Table 10: Product Profile - Azilect
  • Table 11: Azilect SWOT Analysis, 2014
  • Table 12: Global Sales Forecasts ($m) for Azilect, 2012-2022

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
Back to Top